What sector does Saroja Pharma Indus Ind L belong to?

Saroja Pharma Indus Ind L operates in the Commodities sector, specifically the Specialty Chemicals industry, and is listed on the NSE.

What is the current share price of SAROJA?

As of the latest available quote, SAROJA traded at ₹41.00. This price is delayed and cached for about 15 minutes.

What is the P/E ratio of SAROJA?

Saroja Pharma Indus Ind L has a price-to-earnings (P/E) ratio of about 15.95. The P/E ratio compares the share price to earnings per share and is most useful when compared with sector peers and the company's own history.

What is the market capitalisation of SAROJA?

The market capitalisation of Saroja Pharma Indus Ind L is approximately ₹16 Cr.

Is Saroja Pharma Indus Ind L profitable?

For its latest reported financial year, Saroja Pharma Indus Ind L recorded a net profit margin of about 2.31%.

Does SAROJA pay a dividend?

Saroja Pharma Indus Ind L does not currently show a dividend yield in our data.

What is the return on equity (ROE) of SAROJA?

Saroja Pharma Indus Ind L has a return on equity (ROE) of about 9.83%. ROE measures how much profit a company generates relative to shareholders' equity.

What is the 52-week high and low of SAROJA?

Over the past 52 weeks, SAROJA has traded between a low of ₹28.00 and a high of ₹48.00.

Saroja Pharma Indus Ind L

SAROJA NSE Commodities Specialty Chemicals

₹41.00

-1.56%

Delayed · cached 15 min

Fair value analysis

SAROJA

Saroja Pharma Indus Ind L

₹39.80

Close used for this calculation

₹73.34Fair value

Financial DNA Score

Profitability · Returns · Balance Sheet · Efficiency · Growth

48/100

Profitability9/25

Returns15/25

Balance Sheet6/25

Efficiency18/25

Growth9/25

Average

Quality radar

Consensus fair value

₹73.34

Below FV

▲ +84.3% against the close used

Model range ₹14.91 – ₹120.50

The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.

Price target range & 52-week position

Bear₹14.91Fair value₹73.34Bull₹120.50

FairClose

52-week traded range

52W low ₹28.0052W high ₹49.25

The 52-week range is measured from the stored price history, not estimated.

Valuation summary

Trading below the consensus fair value

Saroja Pharma Indus Ind L closed at ₹39.80, 45.7% below the consensus fair value of ₹73.34 drawn from 9 valuation models.

Financial DNA score 48/100 — Average. P/E of 9.9x against the 20x sector multiple the P/E model uses.

Quantitative summary only — not investment advice.

All valuation models

DCF Valuation

₹58.97

+48.2%

Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10

g=3.7%, r=10%, tg=3%, n=10yr

Graham Number

₹62.29

+56.5%

√(22.5 × EPS × BVPS)

EPS=4.03, BVPS=42.8

Graham Formula

₹59.50

+49.5%

EPS × (8.5 + 2g) × 6.5 ÷ FD_Rate

g=3.7%, FD=7%

P/E Fair Value

₹120.50

+202.8%

EPS × 29.9x (sector P/E)

EPS=4.03, Sector P/E=29.9x

Peter Lynch (PEG)

₹14.91

-62.5%

EPS × Growth% (PEG = 1 is fair)

EPS=4.03, g=3.7%

EV/EBITDA

₹83.08

+108.8%

(EBITDA × 11.9x − Net Debt) ÷ Shares

EBITDA=40M

Book Value (P/B)

₹41.64

+4.6%

BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]

BVPS=42.8, ROE=9.8%, g=3.7%, r=10%

Reverse DCF

₹39.80

+0.0%

Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV

Implied: -2.5% | Historical: 3.7%

Margin of Safety

₹56.49

+41.9%

Avg(DCF, Graham, P/E) × 75% (25% safety buffer)

Avg fair value=75.32, MoS=25%

Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.

Educational data only. Not a recommendation to buy, sell or hold any security.

Fair value analysis

Consensus fair value

Price target range & 52-week position

Valuation summary

All valuation models

Equity Timer